Chemo­Cen­tryx gets new PDU­FA date af­ter ma­jor amend­ment; Nim­i­um launch­es with eye on obe­si­ty

Fol­low­ing talks with the FDA, Chemo­Cen­tryx on Mon­day filed an amend­ment to its ap­pli­ca­tion for ava­co­pan as a treat­ment of an­ti-neu­trophil cy­to­plas­mic au­toan­ti­body (AN­CA)-as­so­ci­at­ed vas­culi­tis …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER